5-Year Survival in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia in a Randomized, Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen

PURPOSE: A randomized trial of oblimersen plus fludarabine/cyclophosphamide (OBL-FC; n = 120) versus FC (n = 121) was conducted in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). The primary end point was met: the complete response (CR) rate, defined as complete or nodular part...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: O'Brien, Susan, Moore, Joseph O., Boyd, Thomas E., Larratt, Loree M., Skotnicki, Aleksander B., Koziner, Benjamin, Chanan-Khan, Asher A., Seymour, John F., Gribben, John, Itri, Loretta M., Rai, Kanti R.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2009
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5321078/
https://ncbi.nlm.nih.gov/pubmed/19738118
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.22.5748
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados